Ivan Borbath

28.2k total citations · 4 hit papers
155 papers, 6.3k citations indexed

About

Ivan Borbath is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Ivan Borbath has authored 155 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 71 papers in Epidemiology and 41 papers in Surgery. Recurrent topics in Ivan Borbath's work include Neuroendocrine Tumor Research Advances (62 papers), Pancreatic and Hepatic Oncology Research (60 papers) and Lung Cancer Research Studies (44 papers). Ivan Borbath is often cited by papers focused on Neuroendocrine Tumor Research Advances (62 papers), Pancreatic and Hepatic Oncology Research (60 papers) and Lung Cancer Research Studies (44 papers). Ivan Borbath collaborates with scholars based in Belgium, France and United States. Ivan Borbath's co-authors include Juan W. Valle, Pascal Hammel, F. Huguet, Catherine Lombard‐Bohas, Dieter Hörsch, Eric Van Cutsem, Philippe Ruszniewski, Jean‐Luc Raoul, Éric Raymond and Denis Smith and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Ivan Borbath

149 papers receiving 6.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

2011 1.8k citations Éric Raymond, Laëtitia Dahan et al. profile →
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

2016 685 citations Jean‐Luc Van Laethem, Ivan Borbath et al. profile →
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 471 citations Juan W. Valle, Ivan Borbath et al. Annals of Oncology profile →
Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

2022 174 citations Pierre H. Deprez, Dermot O’Toole et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ivan Borbath	4.7k	3.3k	2.0k	1.5k	1.4k	155	6.3k
Laëtitia Dahan	3.5k 0.7×	1.9k 0.6×	1.2k 0.6×	1.5k 1.0×	1.7k 1.2×	144	5.3k
Keith Stuart	2.4k 0.5×	2.1k 0.6×	1.3k 0.6×	842 0.6×	840 0.6×	70	4.6k
Catherine Lombard‐Bohas	5.3k 1.1×	5.1k 1.5×	3.6k 1.8×	666 0.4×	628 0.4×	168	6.7k
Massimo Milione	2.3k 0.5×	2.0k 0.6×	1.1k 0.6×	1.2k 0.8×	537 0.4×	185	4.4k
Ángela Lamarca	3.1k 0.6×	1.2k 0.4×	672 0.3×	2.8k 1.9×	1.4k 1.0×	219	4.8k
Maria Di Bartolomeo	4.7k 1.0×	1.1k 0.3×	730 0.4×	1.4k 1.0×	2.4k 1.7×	248	6.5k
Pamela L. Kunz	2.9k 0.6×	2.5k 0.8×	1.8k 0.9×	569 0.4×	712 0.5×	101	4.1k
Caroline Caramella	4.6k 1.0×	969 0.3×	474 0.2×	1.2k 0.8×	2.2k 1.5×	137	6.3k
Jonathan Strosberg	8.1k 1.7×	8.1k 2.4×	5.8k 2.9×	586 0.4×	573 0.4×	291	9.9k
Jorge Barriuso	2.4k 0.5×	859 0.3×	574 0.3×	1.1k 0.7×	908 0.6×	137	4.0k

Countries citing papers authored by Ivan Borbath

Since Specialization

Citations

This map shows the geographic impact of Ivan Borbath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Borbath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Borbath more than expected).

Fields of papers citing papers by Ivan Borbath

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Borbath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Borbath. The network helps show where Ivan Borbath may publish in the future.

Co-authorship network of co-authors of Ivan Borbath

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Borbath. A scholar is included among the top collaborators of Ivan Borbath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Borbath. Ivan Borbath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malka, David, Ivan Borbath, Andre Lopes, et al.. (2025). Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10—Precision Medicine). ESMO Open. 10(5). 104540–104540. 1 indexed citations

Finn, Richard S., Masatoshi Kudo, Ivan Borbath, et al.. (2024). Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology. 42(16_suppl). 4100–4100. 2 indexed citations

Hoorens, Anne, Pieter‐Jan Cuyle, Timon Vandamme, et al.. (2024). Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010–2019. Journal of Neuroendocrinology. 37(1). e13473–e13473. 3 indexed citations

Borbath, Ivan, et al.. (2023). Long‐term clinical and radiological outcomes of endoscopic ultrasound‐guided radiofrequency ablation of benign insulinomas. Clinical Endocrinology. 101(5). 485–490. 7 indexed citations

Bouchart, Christelle, Julie Navez, Ivan Borbath, et al.. (2023). Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial. BMC Cancer. 23(1). 891–891. 6 indexed citations

Lepage, Côme, Astrid Lièvre, Laëtitia Dahan, et al.. (2022). Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study. European Journal of Cancer. 175. 31–40. 13 indexed citations

Borbath, Ivan, Ulrich‐Frank Pape, Pierre H. Deprez, et al.. (2022). ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. Journal of Neuroendocrinology. 34(3). e13105–e13105. 13 indexed citations

Dabadie, P., Stéphan Walrand, Renaud Lhommel, et al.. (2022). Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology. 29(4). 2422–2434. 3 indexed citations

Borbath, Ivan, Rocio García‐Carbonero, Paula Jiménez‐Fonseca, et al.. (2022). The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. European Journal of Cancer. 168. 80–90. 18 indexed citations

10.

Kelley, Robin Kate, Thomas Yau, Ann‐Lii Cheng, et al.. (2021). VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. Annals of Oncology. 33(1). 114–116. 48 indexed citations

11.

Makawita, Shalini, Ghassan K. Abou‐Alfa, Sameek Roychowdhury, et al.. (2020). Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncology. 16(30). 2375–2384. 72 indexed citations

12.

Javle, Milind, Saeed Sadeghi, Sameek Roychowdhury, et al.. (2020). SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis. Annals of Oncology. 31. S219–S219. 2 indexed citations

13.

Javle, Milind, Ivan Borbath, Stephen Clarke, et al.. (2019). Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Annals of Oncology. 30. iv62–iv62. 4 indexed citations

14.

Sørbye, Halfdan, Éric Baudin, Ivan Borbath, et al.. (2018). Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology. 108(1). 54–62. 65 indexed citations

15.

Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of Oncology. 29. viii720–viii720. 33 indexed citations

16.

Jouret‐Mourin, Anne, et al.. (2017). Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement. Neuroendocrinology. 106(2). 158–166. 46 indexed citations

17.

Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations

18.

Borbath, Ivan. (2012). Randomized Controlled Phase 2 Study (RCT) with Tivantinib in pre-treated hepatocellular carcinoma(HCC): Efficacy, Safety, and MET-analysis. Hepatology. 56. 1 indexed citations

19.

Valle, Juan W., Patricia Niccoli, Jean‐Luc Raoul, et al.. (2011). Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET). European Journal of Cancer. 47. 2 indexed citations

20.

Raymond, Éric, Ivan Borbath, Jean‐Luc Raoul, et al.. (2009). Phase III, Randomized, Double-blind Trial of Sunitinib Versus Placebo in Patients With Progressive, Well-differentiated Pancreatic Islet Cell Tumours. Annals of Oncology. 20. 11–11. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact